PE20160431A1 - Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica - Google Patents
Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronicaInfo
- Publication number
- PE20160431A1 PE20160431A1 PE2016000285A PE2016000285A PE20160431A1 PE 20160431 A1 PE20160431 A1 PE 20160431A1 PE 2016000285 A PE2016000285 A PE 2016000285A PE 2016000285 A PE2016000285 A PE 2016000285A PE 20160431 A1 PE20160431 A1 PE 20160431A1
- Authority
- PE
- Peru
- Prior art keywords
- acute
- treatment
- chronic cough
- diaminopyridine
- sub
- Prior art date
Links
- 206010011224 Cough Diseases 0.000 title abstract 2
- 102100040479 P2X purinoceptor 2 Human genes 0.000 title abstract 2
- 101710189968 P2X purinoceptor 2 Proteins 0.000 title abstract 2
- 102100040460 P2X purinoceptor 3 Human genes 0.000 title abstract 2
- 101710189970 P2X purinoceptor 3 Proteins 0.000 title abstract 2
- 208000013116 chronic cough Diseases 0.000 title abstract 2
- 230000001154 acute effect Effects 0.000 title 1
- ZZYXNRREDYWPLN-UHFFFAOYSA-N pyridine-2,3-diamine Chemical compound NC1=CC=CN=C1N ZZYXNRREDYWPLN-UHFFFAOYSA-N 0.000 title 1
- 102000005962 receptors Human genes 0.000 title 1
- 108020003175 receptors Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- BXDKERQVHSVAEI-UHFFFAOYSA-N 5-(5-bromo-4-methoxy-2-propan-2-ylphenoxy)pyrimidine-2,4-diamine Chemical compound C1=C(Br)C(OC)=CC(C(C)C)=C1OC1=CN=C(N)N=C1N BXDKERQVHSVAEI-UHFFFAOYSA-N 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- MISVBCMQSJUHMH-UHFFFAOYSA-N pyrimidine-4,6-diamine Chemical class NC1=CC(N)=NC=N1 MISVBCMQSJUHMH-UHFFFAOYSA-N 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361869174P | 2013-08-23 | 2013-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160431A1 true PE20160431A1 (es) | 2016-06-02 |
Family
ID=52480919
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000285A PE20160431A1 (es) | 2013-08-23 | 2014-08-22 | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US9284279B2 (enExample) |
| EP (2) | EP3865134A1 (enExample) |
| JP (3) | JP6546592B2 (enExample) |
| KR (1) | KR102196885B1 (enExample) |
| CN (1) | CN105682659B (enExample) |
| AU (1) | AU2014308606B2 (enExample) |
| CA (1) | CA2921395C (enExample) |
| CL (3) | CL2016000400A1 (enExample) |
| CR (1) | CR20160093A (enExample) |
| IL (1) | IL244131B (enExample) |
| MX (1) | MX367657B (enExample) |
| MY (1) | MY195728A (enExample) |
| NI (1) | NI201600029A (enExample) |
| NZ (1) | NZ716977A (enExample) |
| PE (1) | PE20160431A1 (enExample) |
| PH (1) | PH12016500357A1 (enExample) |
| RU (1) | RU2650118C2 (enExample) |
| SG (1) | SG11201601145RA (enExample) |
| UA (1) | UA118851C2 (enExample) |
| WO (1) | WO2015027212A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160431A1 (es) * | 2013-08-23 | 2016-06-02 | Afferent Pharmaceuticals Inc | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica |
| JP2017505348A (ja) | 2014-02-10 | 2017-02-16 | パタラ ファーマ リミテッド ライアビリティ カンパニー | 肺疾患治療のための肥満細胞安定剤 |
| PL3104853T3 (pl) | 2014-02-10 | 2020-05-18 | Respivant Sciences Gmbh | Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych |
| WO2017011729A1 (en) | 2015-07-16 | 2017-01-19 | Patara Pharma, LLC | Combination therapies for the treatment of lung diseases |
| WO2017027387A1 (en) | 2015-08-07 | 2017-02-16 | Patara Pharma, LLC | Methods for the treatment of mast cell related disorders with mast cell stabilizers |
| US10265296B2 (en) | 2015-08-07 | 2019-04-23 | Respivant Sciences Gmbh | Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders |
| CA2998742C (en) * | 2015-09-29 | 2023-08-29 | Anthony P. FORD | Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough |
| US9907795B2 (en) * | 2016-01-08 | 2018-03-06 | Nerre Therapeutics Limited | Method of treatment of chronic cough administering orvepitant in combination with other therapeutic agents |
| AU2017237929B2 (en) | 2016-03-25 | 2021-04-15 | Afferent Pharmaceuticals Inc. | Pyrimidines and variants thereof, and uses therefor |
| JP2019528320A (ja) | 2016-08-31 | 2019-10-10 | レシュピファント サイエンシス ゲゼルシャフト ミット ベシュレンクター ハフトゥングＲｅｓｐｉｖａｎｔ Ｓｃｉｅｎｃｅｓ Ｇｍｂｈ | 特発性肺線維症による慢性咳の治療のためのクロモリン組成物 |
| EP3522983A4 (en) | 2016-10-07 | 2020-06-03 | Respivant Sciences GmbH | CROMOLYN COMPOSITION FOR TREATING LUNG FIBROSIS |
| EP3554504B1 (en) | 2016-12-15 | 2022-10-26 | Afferent Pharmaceuticals Inc. | Substituted pyrazole-pyrimidines, variants thereof, and uses thereof |
| MX381790B (es) * | 2016-12-20 | 2025-03-13 | Afferent Pharmaceuticals Inc | Sales cristalinas y polimorfos de un antagonista de p2x3. |
| US10111883B1 (en) * | 2017-09-18 | 2018-10-30 | Bellus Health Cough Inc. | Selective P2X3 modulators |
| CN108904507A (zh) * | 2018-02-11 | 2018-11-30 | 赖英杰 | P2x3受体调节剂苯并咪唑化合物在制备抗呼吸疾病药物中的应用 |
| CN112004551A (zh) | 2018-03-15 | 2020-11-27 | 丹米尔治疗有限责任公司 | 3”,5”-二烷氧基苯甲酰基-3’-氨基-3’-脱氧腺苷-5’-三磷酸及其药物用途 |
| WO2019209607A1 (en) * | 2018-04-23 | 2019-10-31 | Merck Sharp & Dohme Corp. | Novel process for synthesis of a phenoxy diaminopyrimidine compound |
| MA52616A (fr) | 2018-05-15 | 2021-03-24 | Bayer Ag | Benzamides à substitution 1,3-thiazol-2-yl pour le traitement de maladies associées à la sensibilisation de fibres nerveuses |
| SG11202011010YA (en) * | 2018-05-15 | 2020-12-30 | Bayer Ag | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
| CN118512451A (zh) * | 2018-07-23 | 2024-08-20 | 特雷维治疗股份有限公司 | 慢性咳嗽、呼吸急促和呼吸困难的治疗 |
| CN113164488A (zh) * | 2018-10-05 | 2021-07-23 | 盐野义制药株式会社 | 慢性咳嗽治疗用药物 |
| DK3880678T3 (da) | 2018-11-13 | 2025-06-10 | Glaxosmithkline Intellectual Property No 3 Ltd | Krystallinske former af p2x3-modulator methyl(s)-2-((2-(2,6-difluoro-4-(methylcarbamoyl )phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholin-4-carboxylat |
| CA3131312A1 (en) | 2019-02-25 | 2020-09-03 | Bellus Health Cough Inc. | Treatment with p2x3 modulators |
| EP3960179B1 (en) * | 2019-04-30 | 2026-03-18 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating cough by using diaminopyrimidine compound |
| ES3056709T3 (en) * | 2019-04-30 | 2026-02-24 | Beijing Tide Pharmaceutical Co Ltd | Salt of diaminopyrimidine compounds, and solid form thereof, preparation method therefor and use thereof |
| MA56022A (fr) | 2019-05-31 | 2022-04-06 | Chiesi Farm Spa | Dérivés d'amino quinazoline servant d'inhibiteurs de p2x3 |
| CN117843615A (zh) | 2019-09-19 | 2024-04-09 | 盐野义制药株式会社 | 1,3,5-三嗪衍生物或其溶剂合物的晶体及其制造方法 |
| IL294601A (en) | 2020-01-10 | 2022-09-01 | Trevi Therapeutics Inc | Methods of administration of nalbuphine |
| CN111635368B (zh) * | 2020-06-12 | 2021-06-29 | 东莞市东阳光仿制药研发有限公司 | 一种胺化合物的制备方法 |
| EP4604089A1 (en) | 2022-10-12 | 2025-08-20 | SoftBank Group Corp. | Information processing system, information processing device, control device, and program |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1725540E (pt) * | 2004-03-05 | 2012-11-29 | Hoffmann La Roche | Diaminopirimidinas como antagonistas de p2x3 e p2x2/3 |
| WO2006012639A2 (en) | 2004-07-22 | 2006-02-02 | Duska Scientific Co. | Method of diagnosing, monitoring and treating pulmonary diseases |
| ATE529413T1 (de) * | 2005-09-01 | 2011-11-15 | Hoffmann La Roche | Verfahren zur synthese von aryloxydiaminopyrimidinen |
| SI1924264T1 (sl) | 2005-09-01 | 2013-12-31 | F. Hoffmann-La Roche Ag | Diaminopirimidini kot modulatorji p2x3 in p2x2/3 |
| ES2612890T3 (es) * | 2005-09-01 | 2017-05-19 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores de P2X3 y P2X2/3 |
| ES2562056T3 (es) | 2005-09-01 | 2016-03-02 | F. Hoffmann-La Roche Ag | Diaminopirimidinas como moduladores P2X3 y P2X2/3 |
| DK2343281T3 (en) * | 2006-10-04 | 2014-03-24 | Hoffmann La Roche | Process for the Synthesis of Phenoxydiamino-Pyrimidine Derivatives |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| JP6124351B2 (ja) * | 2012-02-09 | 2017-05-10 | 塩野義製薬株式会社 | 複素環および炭素環誘導体 |
| PE20160431A1 (es) | 2013-08-23 | 2016-06-02 | Afferent Pharmaceuticals Inc | Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica |
| US9222282B2 (en) * | 2013-10-11 | 2015-12-29 | Nexkey, Inc. | Energy efficient multi-stable lock cylinder |
-
2014
- 2014-08-22 PE PE2016000285A patent/PE20160431A1/es unknown
- 2014-08-22 SG SG11201601145RA patent/SG11201601145RA/en unknown
- 2014-08-22 JP JP2016536497A patent/JP6546592B2/ja active Active
- 2014-08-22 AU AU2014308606A patent/AU2014308606B2/en active Active
- 2014-08-22 WO PCT/US2014/052389 patent/WO2015027212A1/en not_active Ceased
- 2014-08-22 CA CA2921395A patent/CA2921395C/en active Active
- 2014-08-22 RU RU2016105581A patent/RU2650118C2/ru active
- 2014-08-22 EP EP21159088.0A patent/EP3865134A1/en active Pending
- 2014-08-22 CN CN201480058491.3A patent/CN105682659B/zh active Active
- 2014-08-22 EP EP14838254.2A patent/EP3035932A4/en not_active Withdrawn
- 2014-08-22 KR KR1020167007167A patent/KR102196885B1/ko active Active
- 2014-08-22 NZ NZ716977A patent/NZ716977A/en unknown
- 2014-08-22 US US14/466,713 patent/US9284279B2/en active Active
- 2014-08-22 MX MX2016002289A patent/MX367657B/es active IP Right Grant
- 2014-08-22 UA UAA201601740A patent/UA118851C2/uk unknown
- 2014-08-22 MY MYPI2016000327A patent/MY195728A/en unknown
- 2014-08-22 CR CR20160093A patent/CR20160093A/es unknown
-
2016
- 2016-02-02 US US15/013,798 patent/US9724346B2/en active Active
- 2016-02-15 IL IL244131A patent/IL244131B/en active IP Right Grant
- 2016-02-22 NI NI201600029A patent/NI201600029A/es unknown
- 2016-02-22 CL CL2016000400A patent/CL2016000400A1/es unknown
- 2016-02-23 PH PH12016500357A patent/PH12016500357A1/en unknown
-
2017
- 2017-08-01 US US15/665,595 patent/US10206922B2/en active Active
-
2018
- 2018-08-08 CL CL2018002137A patent/CL2018002137A1/es unknown
- 2018-08-08 CL CL2018002138A patent/CL2018002138A1/es unknown
-
2019
- 2019-03-25 JP JP2019055849A patent/JP7210348B2/ja active Active
-
2022
- 2022-10-18 JP JP2022166618A patent/JP7423725B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2019005192A (es) | Compuestos de quinolina selectivamente sustituida. | |
| UY35288A (es) | Piridonamidas como moduladores de canales de sodio | |
| MX390698B (es) | Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos. | |
| UA113440C2 (xx) | Сполуки тетрагідропіразолопіримідину | |
| CY1125963T1 (el) | Ρυθμιστες υποδοχεα ρ2χ3 και ρ2χ2/3 διαμινοπυριμιδινης για χρηση στη θεραπεια βηχα | |
| MX2016004629A (es) | Compuestos de quinolina selectivamente sustituidos. | |
| NI201600029A (es) | Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para el tratamiento de la tos aguda, sub-aguda o crónica. | |
| MX2021006804A (es) | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. | |
| TR201902516T4 (tr) | Glukagon-glp-1-gıp üçlü agonist bileşikleri. | |
| PE20170325A1 (es) | Compuestos y composiciones como agonistas del receptor tipo toll | |
| CL2013002664A1 (es) | Compuestos derivados heterociclicos de amina; afines a receptores asociados a mina traza taar1; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento o profilaxis de la depresion, ansiedad, parkinson, trastorno bipolar, de hiperactividad con deficit atencional, relacionados con estres, y otros. | |
| MX362995B (es) | Derivado de aminotriazina y composicion farmaceutica que comprende el mismo. | |
| DOP2016000333A (es) | Sales cristalinas de (s)-6-((1-acetilpiperidin-4-il)amino)-n-(3-(3,4-dihidroisoquinolin-2(1h)-il)-2-hidroxipropil)pirimidino-4-carboxamida | |
| PE20151536A1 (es) | Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina | |
| ECSP14030538A (es) | Inhibidores de dgat1 de éter cíclico de cabeza de puente | |
| MX381819B (es) | Derivados de heterociclico opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas oncológicas y autoinmunitarias. | |
| UY31933A (es) | Compuestos de sulfoximinamida para combatir plagas animales | |
| PE20151429A1 (es) | Dihidropirimidinonas biciclicas sustituidas y su uso como inhibidores de la actividad de elastasa neutrofilica | |
| EP2903972A4 (en) | SUBSTITUTED N- (3- (PYRIMIDIN-4-YL-) PHENYL-) ACRYLAMIDE ANALOGUE AS TYROSINE RECEPTOR KINASE-BTK INHIBITORS | |
| EA201690846A1 (ru) | Замещенные производные пиридина, пригодные в качестве ингибиторов gsk-3 | |
| JOP20150177B1 (ar) | مركبات 6 ، 7 ثاني هيدرو بيرازولو [ 1، 5 الفا ] بيرازين – 4 (5 يد) – اون واستخدامها كمنظمات الوسترية سلبية لمستقبلات ملجور 2 | |
| MX373079B (es) | Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartílago. | |
| PE20170184A1 (es) | Derivados de piperidina como antagonista de receptores de orexina | |
| MX2015009155A (es) | Uso de agonistas del receptor nicotinico de acetilcolina alfa 7. | |
| PE20180357A1 (es) | Derivados de etinilo |